Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2011109298) THERAPEUTIC DLL4 BINDING PROTEINS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2011/109298 International Application No.: PCT/US2011/026489
Publication Date: 09.09.2011 International Filing Date: 28.02.2011
IPC:
C07K 16/18 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
Applicants:
ABBVIE INC. [US/US]; 1 North Waukegan Road North Chicago, IL 60064, US (AllExceptUS)
LI, Yingchun [CN/US]; US (UsOnly)
GU, Jijie, James [US/US]; US (UsOnly)
MORGAN-LAPPE, Susan [US/US]; US (UsOnly)
CHEN, Mingjiu [US/US]; US (UsOnly)
HSIEH, Chung-Ming [US/US]; US (UsOnly)
Inventors:
LI, Yingchun; US
GU, Jijie, James; US
MORGAN-LAPPE, Susan; US
CHEN, Mingjiu; US
HSIEH, Chung-Ming; US
Agent:
REININGER, Irene, M.; Abbott Laboratories 100 Abbott Park Road AP6A-1/D0377 Abbott Park, IL 60064, US
Priority Data:
61/309,49402.03.2010US
Title (EN) THERAPEUTIC DLL4 BINDING PROTEINS
(FR) PROTÉINES THÉRAPEUTIQUES DE LIAISON À DLL4
Abstract:
(EN) DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
(FR) La présente invention concerne des protéines de liaison à DLL4, comprenant des anticorps, des anticorps greffés CDR, des anticorps humanisés, et leurs fragments de liaison à DLL4, des protéines se liant à DLL4 avec une affinité élevée, et des protéines de liaison à DLL4 qui neutralisent l'activité DLL4 et/ou VEGF. Les protéines de liaison à DLL4 sont utiles dans le traitement ou la prévention de cancers et de tumeurs, et plus particulièrement dans le traitement ou la prévention de l'angiogenèse tumorale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
UAa201211363UY0001033254AR080452EP2542582IL221714JP2013520993
CN102906113SG183872CA2791631RU2012141881DOP2012000240CR55/20120454
PA20118918901CL2012002416EC2012012194SG10201501562VKR1020120135419CN105037543
EP3072904JP2016185961NZ602734RU0002605928AU2015202980AU2011223919
VN33011MYPI 2012700595PH1/2012/501720TH148732IN8528/DELNP/2012KR1020180044441